Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. METHODS: vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone. CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the FDA has approved AAV for gene replacement therapy in spinal muscular atrophy and congenital blindness, and clinical trials are in progress 58 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [58]
In the citing paper
“preclinical and clinical studies have demonstrated dose-dependent inflammation, which can reduce efficacy and lead to dose-limiting toxicity (2–8)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [4]
In the citing paper
“Although neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, sometimes that is related to head motion that occurred during the scan which can erode signal 61”
From Autism spectrum disorder (2020) · cites this paper as [61]
In the citing paper
“Especially considering the ability of the recombinant AAV genome to persist as an episome in post-mitotic cells, such as neurons, which ensures long-term expression even after a single administration [130-132].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [132]
In the citing paper
“With AAV9’s inherent ability to target motor neurons, AAV9-based Zolgensma® for the treatment of SMA has been established as the first FDA-approved drug for systemic gene therapy in CNS diseases [171].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [171]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
Self-citationRetractedDeaths: preliminary data for 2003.
Hoyert, D. L., Kung, H.-C., & Smith, B. L. (2005) · PubMed · Cited by 1,649
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citationBayley Scales of Infant and Toddler Development, Third Edition
Bayley, N. (2012) · PsycTESTS Dataset · doi:10.1037/t14978-000 · Cited by 1,175
National Vital Statistics Reports NCHS.pdf
Hoyert, D. (2012) · Medical Entomology and Zoology · Cited by 982
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961 · cited 4×
“Viral upper respiratory tract infection 0 0 3 3 (25) 3 3 (20)”
InfluentialAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
de Onis, M., Onyango, A. W., Van den Broeck, J., Chumlea, W. C., & Martorell, R. (2004) · Food and Nutrition Bulletin · doi:10.1177/15648265040251s105 · Cited by 529
Research works printed but not linked: 1
- Hoyert DL, 2012, Natl Vital Stat Rep, 61, 1
Cited by
Items 301–400 of 1,005
Mücke, M. M., Fong, S., Foster, G. R., Lillicrap, D., Miesbach, W., & Zeuzem, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.029 · Cited by 81
AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials
Hardcastle, N., Boulis, N. M., & Federici, T. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1416089 · Cited by 70
“While ubiquitous gene expression could be advantageous in conditions where multiple systems are involved, transient liver toxicity has been reported at life-threatening levels in a couple of patients in the current SMA trial [44].”
BackgroundMorelli, K. H., Griffin, L. B., Pyne, N. K., Wallace, L. M., Fowler, A. M., Oprescu, S. N., Takase, R., Wei, N., Meyer‐Schuman, R., Mellacheruvu, D., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130600 · Cited by 74
“Gene therapy approaches are now in the clinic to treat recessive loss-of-function conditions by restoring the expression of the mutated genes (6, 7).”
BackgroundMND-Net, T., Wurster, C. D., Steinacker, P., Günther, R., Koch, J. C., Lingor, P., Uzelac, Ž., Witzel, S., Wollinsky, K. H., Winter, B., et al. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09547-y · Cited by 75
Alstyne, M. V., Simon, C. M., Sardi, S. P., Shihabuddin, L. S., Mentis, G. Z., & Pellizzoni, L. (2018) · Genes & Development · doi:10.1101/gad.316059.118 · Cited by 83
“…emerging but comprehensive understanding of what aspects of SMA pathology are insufficiently addressed in patients is lacking (Finkel et al. 2017; Mendell et al. 2017), there is increasing interest in the identification of combinatorial approaches that might complement SMN-based therapeutics…”
BackgroundKichula, E. A., Proud, C. M., Farrar, M. A., Kwon, J. M., Saito, K., Desguerre, I., & McMillan, H. J. (2021) · Muscle & Nerve · doi:10.1002/mus.27363 · Cited by 77
“SMA patients are treated with prophylactic prednisolone with the goal of attenuating serum aminotransferase elevations.(28) Starting 1 day before onasemnogene abeparvovec infusion, systemic corticosteroids”
BackgroundFinkel, R. S., Darras, B. T., Mendell, J. R., Day, J., Kuntz, N. L., Connolly, A. M., Zaidman, C. M., Crawford, T. O., Butterfield, R. J., Shieh, P. B., et al. (2023) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-221560 · Cited by 70
Self-citationFarrar, M. A., Carey, K. A., Paguinto, S.-G., Chambers, G. M., & Kasparian, N. A. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020907 · Cited by 76
Hughes, M. P., Smith, D. A., Morris, L., Fletcher, C., Colaço, A., Huebecker, M., Tordo, J., Palomar, N., Massaro, G., Henckaerts, E., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy212 · Cited by 74
“effective clinical efficacy for haemophilia using AAV8 (36) and spinal muscular atrophy using AAV9 (37).”
MethodEmerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis
Ly, C. V., & Miller, T. M. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000594 · Cited by 70
Zhou, M., Hu, Z., Qiu, L., Zhou, T., Feng, M., Hu, Q., Zeng, B., Li, Z., Sun, Q., Wu, Y. C., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.255 · Cited by 74
“The second category comprises gene therapy, usually relying on viral vectors such as scAAV9s and lentiviruses to insert SMN cDNA 41–43 or replace exon 1 of the SMN1/2 genes with functional SMN cDNA in the host genome.”
Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy
Kariyawasam, D. S. T., D’Silva, A., Lin, C. S.-Y., Ryan, M. M., & Farrar, M. A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00898 · Cited by 77
“Onasemnogene Abeparvovec (Zolgensma) is a one-time SMN1 gene replacement therapy that may be administered intravenously or intrathecally (19).”
BackgroundZhou, C., Hu, X., Tang, C., Liu, W., Wang, S., Zhou, Y., Zhao, Q., Bo, Q., Shi, L., Sun, X., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa033 · Cited by 69
Spinal Muscular Atrophy: Past, Present, and Future.
Ross, L., & Kwon, J. (2019) · NeoReviews · doi:10.1542/neo.20-8-e437 · Cited by 63
Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy
Jalali, A., Rothwell, E., Botkin, J. R., Anderson, R. A., Butterfield, R. J., & Nelson, R. E. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.07.033 · Cited by 71
Manini, A., Abati, E., Nuredini, A., Corti, S. P., & Comi, G. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.814174 · Cited by 82
“In clinical trials enrolling spinal muscular atrophy (SMA) and DMD patients, a significant elevation of liver enzymes was described, although it was controlled with corticosteroids with no relevant clinical impact (39, 60, 77).”
BackgroundWang, L., Yang, Y., Breton, C., Bell, P., Li, M., Zhang, J., Che, Y., Saveliev, A., He, Z., White, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax5701 · Cited by 67
Weiss, A. R., Liguore, W. A., Domire, J. S., Button, D. A., & McBride, J. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-63559-7 · Cited by 69
In Vivo Repair of a Protein Underlying a Neurological Disorder by Programmable RNA Editing
Sinnamon, J. R., Kim, S. Y., Fisk, J. R., Song, Z., Nakai, H., Jeng, S., McWeeney, S. K., & Mandel, G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107878 · Cited by 67
Friese, J., Geitmann, S., Holzwarth, D., Müller, N., Sassen, R., Baur, U., Adler, K., & Kirschner, J. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200593 · Cited by 73
“Clinical trials for onasemnogene abeparvovec include only SMA type 1 patients up to the age of 8 months [6].”
BackgroundType I SMA “new natural history”: long‐term data in nusinersen‐treated patients
Pane, M., Coratti, G., Sansone, V., Messina, S., Catteruccia, M., Bruno, C., Sframeli, M., Albamonte, E., Pedemonte, M., D’Amico, A., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51276 · Cited by 70
Fischell, J., & Fishman, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.747726 · Cited by 56
Evolving AAV-delivered therapeutics towards ultimate cures
He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 73
“In many other diseases, much higher AAV doses are needed to convey therapeutic benefits from transgenes expression and have been reported to be associated with severe toxicity [15, 16, 26].”
BackgroundAutism spectrum disorder: prospects for treatment using gene therapy
Benger, M., Kinali, M., & Mazarakis, N. (2018) · Molecular Autism · doi:10.1186/s13229-018-0222-8 · Cited by 63
“In addition, a clinical trial in SMA by AveXis using systemic delivery of recombinant adeno-associated virus 9 (rAAV9) carrying a replacement SMN1 gene recently proved safe and efficacious in neonates [16].”
Current Treatment Options in Neurology—SMA Therapeutics
Waldrop, M. A., & Kolb, S. J. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0568-z · Cited by 72
Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB
Kimura, S., & Harashima, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121216 · Cited by 65
“However, most of the gene vectors used in the above reports are administered by invasive local injection, and such brain targeting continues to be a challenge, although Zolgensma, an intravenously administered gene therapy for SMA, was approved in 2019 [24,25].”
BackgroundThomas, S., Conway, K. M. C., Fapo, O., Street, N., Mathews, K. D., Mann, J. R., Romitti, P. A., Soim, A. S., Westfield, C. P., Fox, D. J., et al. (2022) · Muscle & Nerve · doi:10.1002/mus.27532 · Cited by 65
“The task force developed a tool to assist health-care providers in early identification and evaluation of children with motor delay with the goal of decreasing the age at pediatric neuromuscular disease diagnosis, including DMD. 16 This resource includes a modified algorithm emphasizing early CK testing in children wi…”
BackgroundInfluentialDaci, R., & Flotte, T. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021050 · Cited by 81
“Subsequently, a wide variety of single gene disorders affecting the central nervous system have been addressed with rAAV gene therapy, with the rAAV9 vector for spinal muscular atrophy being the first one to be FDA-approved [13].”
BackgroundAronson, S. J., Veron, P., Collaud, F., Hubert, A., Delahais, V., Honnet, G., de Knegt, R. J., Junge, N., Baumann, U., Di Giorgio, A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.143 · Cited by 65
Luoni, M., Giannelli, S., Indrigo, M. T., Niro, A., Massimino, L., Iannielli, A., Passeri, L., Russo, F., Morabito, G., Calamita, P., et al. (2020) · eLife · doi:10.7554/elife.52629 · Cited by 65
McCray, B. A., & Scherer, S. S. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01099-2 · Cited by 71
Aslesh, T., & Yokota, T. (2022) · Cells · doi:10.3390/cells11030417 · Cited by 72
“7 × 1013 vg/kg (n = 3) or a higher dose of 2 × 1014 vg/kg (n = 12) of the AAV9SMN gene under the control of a hybrid CMV enhancer/CBA promoter (NCT02122952) [78].”
BackgroundInfluentialPalmieri, M., Pozzer, D., & Landsberger, N. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1172805 · Cited by 73
“, 2016) as demonstrated in mice and large animal models (Foust et al., 2009; Bevan et al., 2011; Mendell et al., 2017).”
BackgroundCurrent Landscape of Heart Failure Gene Therapy
Kieserman, J. M., Myers, V. D., Dubey, P. K., Cheung, J. Y., & Feldman, A. M. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012239 · Cited by 68
Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome
Collaud, F., Bortolussi, G., Guianvarc’h, L., Aronson, S. J., Bordet, T., Veron, P., Charles, S., Vidal, P., Sola, M. S., Rundwasser, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.011 · Cited by 63
Fetal Gene Therapy Using a Single Injection of Recombinant AAV9 Rescued SMA Phenotype in Mice
Rashnonejad, A., Chermahini, G. A., Gündüz, C., Önay, H., Aykut, A., Durmaz, B., Baka, M., Su, Q., Gao, G., & Özkınay, F. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.017 · Cited by 65
“The ability of adeno-associated virus (AAV) to deliver SMA therapeutic vectors has previously been demonstrated to transduce motor neurons and alleviate disease symptoms in both preclinical and clinical studies for SMA gene therapy.(13,14) These studies finally led to the first FDA-approved AAV-based gene therapy trea…”
BackgroundNon-viral strategies for delivering genome editing enzymes
Li, J., Røise, J. J., He, M., Das, R., & Murthy, N. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.004 · Cited by 68
Translation of New and Emerging Therapies for Genetic Cardiomyopathies
Helms, A. S., Thompson, A. D., & Day, S. M. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.07.012 · Cited by 72
Kumar, R., Le, N., Oviedo, F., Brown, M. E., & Reineke, T. M. (2022) · JACS Au · doi:10.1021/jacsau.1c00467 · Cited by 69
Efficient Gene Transfer to Kidney Mesenchymal Cells Using a Synthetic Adeno-Associated Viral Vector
Ikeda, Y., Sun, Z. Q., Xiao, R., Vandenberghe, L. H., & Humphreys, B. D. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018040426 · Cited by 70
TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinson’s Disease
Zhu, G., Harischandra, D. S., Ghaisas, S., Zhang, P., Prall, W., Huang, L., Maghames, C., Guo, L., Luna, E., Mack, K. L., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108418 · Cited by 63
“, 2018), and its potential is emphasized by recent positive outcomes in clinical trials (Mendell et al., 2017).”
BackgroundDrug treatment for spinal muscular atrophy types II and III
Wadman, R. I., van der Pol, W. L., Bosboom, W. M., Asselman, F., van den Berg, L. H., Iannaccone, S. T., & Vrancken, A. F. J. E. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006282.pub5 · Cited by 79
Ng, J., Barral, S., Barrigon, C. D. L. F., Lignani, G., Erdem, F. A., Wallings, R. L., Privolizzi, R., Rossignoli, G., Alrashidi, H., Heasman, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1564 · Cited by 63
van der Heul, M., Cuppen, I., Wadman, R. I., Asselman, F., Schoenmakers, M. A. G. C., van der Woude, D. R., Gerrits, E., van der Pol, W. L., & van den Engel-Hoek, L. (2020) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190465 · Cited by 67
RNA processing in skeletal muscle biology and disease
Hinkle, E. R., Wiedner, H. J., Black, A. J., & Giudice, J. (2019) · Transcription · doi:10.1080/21541264.2018.1558677 · Cited by 63
“[169] Mendell JR, Al-Zaidy S, Shell R, et al.”
BackgroundHemophilia Gene Therapy: Approaching the First Licensed Product
Batty, P. A., & Lillicrap, D. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000540 · Cited by 66
Current and emerging treatment modalities for spinocerebellar ataxias
Ghanekar, S. D., Kuo, S., Staffetti, J. S., & Zesiewicz, T. A. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2029703 · Cited by 65
Hjartarson, H. T., Nathorst-Böös, K., & Sejersen, T. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s214174 · Cited by 72
“The treatment overall resulted in survival and achievement of motor milestones and motor function incompatible with the natural course of the disease.(28) Subsequently, an open-label Phase 3 study, CL-303 (STR1VE-US), was carried out in USA on 22 patients younger than 6 months with SMA type 1 and 2 SMN2 copies, as a s…”
BackgroundInfluentialStanton, A., Lagerborg, K., Tellez, L., Krunnfusz, A., King, E., Ye, S., Solomon, I., Tabebordbar, M., & Sabeti, P. C. (2022) · i Medicina · doi:10.1016/j.medj.2022.11.002 · Cited by 53
AAV Engineering for Improving Tropism to the Central Nervous System
Ghauri, M. S., & Ou, L. (2023) · Biology · doi:10.3390/biology12020186 · Cited by 73
“These advancements allowed for significant strides in CNS gene therapy, as seen with lysosomal storage diseases like mucopolysaccharidosis [25,34], glioblastoma multiforme [27,28,35], spinal muscular atrophy [36,37], amyotrophic lateral sclerosis [28–40], or Huntington disease [31–43].”
BackgroundAdeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy
Zwi‐Dantsis, L., Mohamed, S., Massaro, G., & Moeendarbary, E. (2025) · Viruses · doi:10.3390/v17020239 · Cited by 77
“In its clinical trial, all of the first 15 treated patients remained event-free at 20 months of age, a significant improvement compared to the 8% survival rate observed in a historical cohort [121].”
Nusinersen for SMA: expanded access programme
Farrar, M. A., Teoh, H. L., Carey, K. A., Cairns, A. G., Forbes, R., Herbert, K., Holland, S., Jones, K., Menezes, M. P., Morrison, M., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317412 · Cited by 63
Vidal‐Folch, N., Gavrilov, D. K., Raymond, K., Rinaldo, P., Tortorelli, S., Matern, D., & Oglesbee, D. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.293712 · Cited by 65
Towards a therapy for mitochondrial disease: an update
Garone, C., & Viscomi, C. F. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180134 · Cited by 68
Next-generation muscle-directed gene therapy by in silico vector design
Sarcar, S., Tulalamba, W., Rincón, M. Y., Tipanee, J., Pham, H. Q., Evens, H., Boon, D., Samara-Kuko, E., Keyaerts, M., Loperfido, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08283-7 · Cited by 61
Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors
Krishnamurthy, S., Traore, S., Cooney, A. L., Brommel, C. M., Kulhánková, K., Sinn, P. L., Newby, G. A., Liu, D. R., & McCray, P. B. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab788 · Cited by 65
Reilly, A., Chehadé, L., & Kothary, R. (2022) · Gene Therapy · doi:10.1038/s41434-022-00349-y · Cited by 72
“Impressively, of the 12 patients who received the higher dose, 11 could sit unassisted, speak, and feed orally, while 2 could walk at 20 months of age [29].”
BackgroundClinical applications of gene therapy for rare diseases: A review
Papaioannou, I., Owen, J. S., & Yáñez‐Muñoz, R. J. (2023) · International Journal of Experimental Pathology · doi:10.1111/iep.12478 · Cited by 79
“Zolgensma performed very well in clinical trials, 196– 200 , 205 showing both a high response rate and substantial substantial Although the evidence so far points to a higher efficacy and response rate for Zolgensma compared with Spinraza, safety concerns with the use of AAV9 use have emerged.”
BackgroundMicro/nanosystems for controllable drug delivery to the brain
Tian, M., Ma, Z., & Yang, G. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100548 · Cited by 80
Czibere, L., Burggraf, S., Fleige, T., Glück, B., Keitel, L. M., Landt, O., Durner, J., Röschinger, W., Hohenfellner, K., Wirth, B., et al. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0476-4 · Cited by 70
Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine
Khatib, T. Z., & Martin, K. R. G. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1663385 · Cited by 67
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
“They are also adopted in approved gene therapies for inherited retinal dystrophy (25) and spinal muscle atrophy (SMA) (26).”
BackgroundOptimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV
Kararoudi, M. N., Likhite, S. B., Elmas, E., Yamamoto, K., Schwartz, M., Sorathia, K., Pereira, M. D. S. F., Sezgin, Y., Devine, R. D., Lyberger, J. M., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100236 · Cited by 73
“The transgenes cloned into ssAAV or scAAV plasmids were packaged in AAV6 capsids as described before (Mendell et al., 2017).”
MethodSelf-citationPinton, L., Khedr, M., Lionello, V. M., Sarcar, S., Maffioletti, S. M., Dastidar, S., Négroni, E., Choi, S., Khokhar, N., Bigot, A., et al. (2023) · Nature Protocols · doi:10.1038/s41596-022-00790-8 · Cited by 76
Brain gene therapy with Trojan horse lipid nanoparticles
Pardridge, W. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.004 · Cited by 64
“Concluding remarks The current clinical development of brain gene therapy utilizes viral vectors such as recombinant adenoassociated virus (rAAV), which have been FDA approved as single-use therapeutics for brain diseases such as spinal muscular atrophy [76].”
BackgroundOverview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy
Shorrock, H. K., Gillingwater, T. H., & Groen, E. J. N. (2018) · Drugs · doi:10.1007/s40265-018-0868-8 · Cited by 67
“Moreover, although drugs like Spinraza and AVXS-101 lead to increased survival, little is known as yet about the quality of life as perceived by the treated patients and their families.”
BackgroundInfluentialWasala, N. B., Yue, Y., Lostal, W., Wasala, L. P., Niranjan, N., Hajjar, R. J., Babu, G. J., & Duan, D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.011 · Cited by 63
“Systemic AAV9 therapy has yielded unprecedented success in treating neuromuscular diseases in human patients.(8) Two clinical trials have also been initiated to test systemic AAV9 gene therapy in DMD patients.”
BackgroundNovel therapies for mucopolysaccharidosis type III
Yılmaz, B. Ş., Davison, J. E., Jones, S. A., & Baruteau, J. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12316 · Cited by 71
Dean, R., Jensen, I. S., Cyr, P. L., Miller, B., Maru, B. S., Sproule, D. M., Feltner, D. E., Wiesner, T., Malone, D. C., Bischof, M., et al. (2021) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2021.1889841 · Cited by 63
“onasemnogene abeparvovec: AVXS-101-CL-101 [NCT02122952][8,28] nusinersen: ENDEAR [NCT02193074][17] and SHINE [NCT02594124][16] BSC: No sitting/walking patients.”
MethodSelf-citationRNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases
Germain, N. D., Chung, W. K., & Sarmiere, P. D. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101148 · Cited by 65
Amado, D. A., Rieders, J. M., Diatta, F., Hernandez-Con, P., Singer, A., Mak, J. T., Zhang, J., Lancaster, E., Davidson, B. L., & Chen-Plotkin, A. S. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.013 · Cited by 58
“We selected AAV serotype 9 (AAV9) based on its ability to broadly disperse and infect neurons and glia after CSF delivery, as well as its prior track record.(28,34,39) We also tested AAV serotype 4 (AAV4), due to its ependymal selectivity and safety profile,(30,40,41) to maximize CSF secretion with the goal of broad C…”
MethodStrategies for fighting mitochondrial diseases
Viscomi, C. F., & Zeviani, M. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13046 · Cited by 66
Restoring the natural tropism of AAV2 vectors for human liver
Cabanes-Creus, M., Hallwirth, C. V., Westhaus, A., Ng, B. H., Liao, S. H. Y., Zhu, E., Navarro, R. G., Baltazar, G., Drouyer, M., Scott, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba3312 · Cited by 58
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
“Then, Luxturna, an AAV2-based gene therapy for retinal diseases (8), was approved in the USA in 2017, and Zolgensma, an AAV9-based gene therapy for spinal muscular atrophy in the USA in 2019 (9).”
MethodInfluentialCornel, M. C., Rigter, T., Jansen, M. E., & Henneman, L. (2020) · Journal of Community Genetics · doi:10.1007/s12687-020-00488-y · Cited by 70
Liu, N., Kataoka, M., Wang, Y., Pu, L., Dong, X., Fu, X., Zhang, F., Gao, F., Liang, T., Pei, J., et al. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-021-00887-3 · Cited by 61
Genetic therapeutic advancements for Dravet Syndrome
Chilcott, E. M., Diaz, J. F. A., Bertram, C., Berti, M., & Karda, R. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108741 · Cited by 62
“Furthermore, Zolgensma (AAV9_SMN1) has been successfully implemented as a single-dose treatment in pre-clinical [77] and clinical trials for Spinal Muscular Atrophy [60], resulting in its recent FDA and EMA approval.”
BackgroundGene Therapy for Mitochondrial Diseases: Current Status and Future Perspective
Donfrancesco, A. D., Massaro, G., Meo, I. D., Tiranti, V., Bottani, E., & Brunetti, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061287 · Cited by 65
“Many successful clinical trials, mainly using viral vectors, have followed, resulting in the more recent commercialization of Luxturna to treat inherited retinal dystrophy [23] and Zolgensma to treat pediatric patients with spinal muscular atrophy [24].”
BackgroundVitale, F., Giliberto, L., Ruiz, S., Steslow, K., Marambaud, P., & d’Abramo, C. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0585-2 · Cited by 57
Martier, R., Liefhebber, J., Miniarikova, J., van der Zon, T., Snapper, J., Kolder, I., Petry, H., van Deventer, S., Evers, M., & Konstantinova, P. (2019) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2019.01.010 · Cited by 53
Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease
Martier, R., Sogorb-González, M., Stricker-Shaver, J., Hübener-Schmid, J., Keskin, S., Klíma, J., Toonen, L., Juhás, Š., Juhásová, J., Ellederová, Z., et al. (2019) · Molecular Therapy: Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.008 · Cited by 49
“semiovaleWM, (53) temporal cortex, (54) temporal lobeWM, (55) insular cortex, (56) caudate, (57) thalamus anterior, (58) thalamus ventral, (59) putamen, (60) globus pallidus,”
Chandler, R. J., Venturoni, L. E., Liao, J., Hubbard, B. T., Schneller, J. L., Hoffmann, V. J., Gordo, S., Zang, S., Ko, C., Chau, N., et al. (2020) · Hepatology · doi:10.1002/hep.31570 · Cited by 61
Ilyinskii, P. O., Michaud, A. M., Roy, C. J., Rizzo, G. L., Elkins, S. L., Capela, T., Chowdhury, A. C., Leung, S. S., & Kishimoto, T. K. (2021) · Science Advances · doi:10.1126/sciadv.abd0321 · Cited by 56
Marrone, L., Marchi, P. M., & Azzouz, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2012148 · Cited by 56
Translational Feasibility of Lumbar Puncture for Intrathecal AAV Administration
Hinderer, C. J., Katz, N., Dyer, C., Goode, T. L., Johansson, J., Bell, P. L., Richman, L. K., Buza, E. L., & Wilson, J. M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.012 · Cited by 57
Presenilin-1 (PSEN1) Mutations: Clinical Phenotypes beyond Alzheimer’s Disease
Yang, Y., Bagyinszky, E., & An, S. S. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098417 · Cited by 65
“The functional replacement of a mutant gene in children with SMA was associated with improved motor function [6].”
BackgroundNair, R. R., Blankvoort, S., Lagartos, M. J., & Kentros, C. (2020) · iScience · doi:10.1016/j.isci.2020.100888 · Cited by 55
Adeno-Associated Virus Vector for Central Nervous System Gene Therapy
Zhu, D., Schieferecke, A. J., Lopez, P. A., & Schaffer, D. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.03.010 · Cited by 56
A User's Guide to the Inverted Terminal Repeats of Adeno-Associated Virus
Wilmott, P., Lisowski, L., Alexander, I. E., & Logan, G. J. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.276 · Cited by 52
Besse, A., Astord, S., Marais, T., Roda, M., Giroux, B., Lejeune, F., Relaix, F., Smeriglio, P., Barkats, M., & Biferi, M. G. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.011 · Cited by 54
“Indeed, elevated aminotransferase levels, an indicator of liver damage, were observed in some AAV9-SMN-treated patients.(10) This, together with severe toxicity, has also been observed in non-human primates (NHPs) and piglets after i.”
BackgroundMethodInfluentialBrain, cognition, and language development in spinal muscular atrophy type 1: a scoping review
Masson, R., Brusa, C., Scoto, M., & Baranello, G. (2021) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14798 · Cited by 62
Díaz-Caneja, C., State, M., Hagerman, R., Jacquemont, S., Marín, O., Bagni, C., Umbricht, D., Simonoff, E., de Andrés-Trelles, F., Kaale, A., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.020 · Cited by 55
Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain
Bajracharya, R., Caruso, A. C., Vella, L. J., & Nisbet, R. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122014 · Cited by 54
“Although SMN is not an antibody, it is roughly the same size as an scFv.”
BackgroundStavrou, M., Kagiava, A., Choudury, S. G., Jennings, M. J., Wallace, L. M., Fowler, A. M., Heslegrave, A., Richter, J., Tryfonos, C., Christodoulou, C., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159814 · Cited by 59
“Regarding the safety of AAV9-based vectors in humans, follow-up studies in AAV9-treated patients with spinal muscular atrophy (SMA) suggested stable beneficial effects of Zolgensma with no major adverse reactions or long-term toxicity (93, 98, 99).”
Genetics and precision genomics approaches to pulmonary hypertension
Austin, E. D., Aldred, M. A., Alotaibi, M., Gräf, S., Nichols, W. C., Trembath, R. C., & Chung, W. K. (2024) · European Respiratory Journal · doi:10.1183/13993003.01370-2024 · Cited by 76
“Several of these therapies are now approved by the US Food and Drug Administration (FDA) and European Medicines Agency and include genetic therapies for diseases such as spinal muscular atrophy and sickle cell disease [1].”
The progress of AAV-mediated gene therapy in neuromuscular disorders
Aguti, S., Malerba, A., & Zhou, H. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1479739 · Cited by 55
“including capabilities of unassisted sitting, oral feeding, speaking, and even independent walking [67,68].”
BackgroundJanzen, E., Mendoza-Ferreira, N., Hosseinibarkooie, S., Schneider, S. M., Hupperich, K., Tschanz, T., Grysko, V., Rießland, M., Hammerschmidt, M., Rigo, F., et al. (2018) · Brain · doi:10.1093/brain/awy167 · Cited by 62
Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease
Rao, V. K., Kapp, D., & Schroth, M. K. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.12-a.s3 · Cited by 77
Murillo, O., Moreno, D., Gázquez, C., Barberia, M., Cenzano, I., Navarro-Blasco, Í., Uriarte, I., Sebastián, V., Arruebo, M., Ferrer, V., et al. (2019) · Hepatology · doi:10.1002/hep.30535 · Cited by 71
“Gene therapy represents a promising therapeutic option for many inherited diseases, as has been recently demonstrated for genetic immunodeficiencies,(27) hemophilia,(28) inherited blindness,(29) or spinal muscular atrophy.(30) Those studies have demonstrated that selection of the proper vector is key for success of th…”
BackgroundKidney organoids in translational medicine: Disease modeling and regenerative medicine
Miyoshi, T., Hiratsuka, K., Saiz, E. G., & Morizane, R. (2019) · Developmental Dynamics · doi:10.1002/dvdy.22 · Cited by 59
Metadata
- Authors
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L’Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K. D., Burghes, A. H. M., & Kaspar, B. K.
- Affiliations
- Abigail Wexner Research Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-02
- Volume
- 377
- Issue
- 18
- Pages
- 1713-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2765253110
- Cited by
- 2,381
- References
- 26
- Citations by year
- 2026: 205 · 2025: 232 · 2024: 292 · 2023: 270 · 2022: 289 · 2021: 347 · 2020: 298 · 2019: 246 · 2018: 172 · 2017: 16
- FWCI
- 115.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nationwide Children's Hospital
- AveXis
- Research Institute, Nationwide Children's Hospital
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- spinal muscular atrophy type 1, gene replacement therapy, adeno-associated virus vectors, SMN1, motor function, motor milestones, survival, CHOP INTEND, aminotransferase elevation, prednisolone, treatment efficacy and safety
- MeSH terms
- Dependovirus, Female, Genetic Vectors, Humans, Infant, Infant, Newborn, Infusions, Intravenous, Liver Diseases, Male, Motor Skills, Respiration, Artificial, Spinal Muscular Atrophies of Childhood, Genetic Therapy, Cohort Studies, Nutritional Support, Disease-Free Survival, Survival of Motor Neuron 1 Protein, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.